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ABSTRACT OF THE THESIS
Constructing a Fluorescence Lifetime Nanoprobe Library to Advance
Lifetime-Based Multiplexing
By
Louis Mejia
Master of Science in Biomedical Engineering
University of California, Irvine, 2019
Assistant Professor Jered B. Haun, Chair
Despite progress of the modern biomedical revolution, efficient personalized cancer
cures remain largely elusive due to the vast amount of potential biomarkers to iden-
tify. This diverse pool of receptors is a product of a complex ecosystem of distinct key
cell types within a tumor which may help promote proliferation. This intra-tumor
heterogeneity has necessitated development of methods to identify key cell type recep-
tors, such as molecular probes that target biomarkers. Probes harboring fluorescent
species are among the most successful and couple distinct-spectra fluorescent species
to a targeting protein, such as an antibody. However, existing probe libraries are
limited to only 10 simultaneous detection channels, severely reducing the amount
of ascertainable molecular information. Fluorescence lifetime imaging microscopy
(FLIM) has been proposed as an expansion to conventional fluorescence imaging by
adding an additional dimension of channels to analyze, but has been limited by the
complexities of curve fitting decay half-lives. Recently, the phasor approach to FLIM
provided an elegant means to analyze species mixtures on a phasor plot. Here, we
demonstrate the construction of a lifetime probe library encapsulating a controlled
ix
loading ratio of fluorescent species and analyzed with the phasor approach to FLIM.
Using a reverse microemulsion synthesis method, organic dyes, dark quenchers, and
quantum dots have been incorporated into probe cores to unlock a variety of distinct
phasor positions within a single spectral window. Probe surfaces may be modified
with polyethylene glycol chains to help prevent in-vitro protein adsorption and a
functional loss of targeting specificity. Bioorthogonal click chemistry linkers may be
conjugated onto chain termini to allow highly specific coupling to analogous premod-
ified antibodies via rapid in-vitro two-step targeting of tumor biomarkers, or through
the formation of immunoconjugates for direct targeting. Subsequently, the presence
of key receptors may be inferred using the phasor approach. With the success of our
preliminary probes, multiplexed targeting assays will follow. Ultimately, we intend
to use our lifetime probe library in clinical settings to efficiently characterize tumors
via simultaneous detection of up to 80 pre-selected personalized biomarkers.
x
Chapter 1
Introduction
At the present time, cancer remains the second leading cause of death in the United
States [57]. This is due to the complex and dynamic heterogeneous microenvironment
of tumors, hosting cell types known to indirectly promote proliferation [4]. There-
fore, a molecular platform which can rapidly identify a vast array of key cell type
biomarkers is necessary to help develop successful personalized treatments. To avoid
the destruction of samples via popular statistically-driven massive-scale techniques,
highly successful fluorescent exogenous probes have been developed for research in
the past decades. Fluorescence lifetime imaging microscopy has been proposed an ex-
pansion to conventional fluorescence spectral imaging, but has been largely hindered
by the inherent complexities of curve fitting decay half-lives. Recently, the phasor
approach to FLIM was pioneered as an elegant way to resolve distinct lifetime species
within the same spectral window by mapping data onto a semicricle phasor plot [12].
However, the phasor approach has not yet reached its full potential due to the lack
of an existing library of probes utilizing this method.
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In this project, we introduce the development of a fluorescence lifetime library of
nanoprobes encapsulating various fluorescent species at controlled loading ratios. We
propose the use of silica as a nanomaterial due its inherent biocompatibility and ease
of surface modification [50, 37, 39]. Furthermore, due to homo-quenching and hetero-
quenching energy transfer between adjacent fluorescent molecules, specific ratios of
species can unlock distinct phasor plot positions to produce a wide array of potential
probes for a lifetime library. Functional groups on silane molecules may be subse-
quently added onto probe exteriors as a basis for further modifications to act as a
protective filler corona to shield probes from the biological environment [9]. Such
modifications could help promote aqueous dissolution and prevent protein adsorption
in targeting applications. Finally, bioorthogonal linker molecules could be conjugated
onto the exteriors of protective corona coatings, intended to couple to corresponding
molecules modified onto antibodies with high specificity in biological settings [43].
A three-part system of functionalized fluorescent probes, modified antibodies, and
tumor cell lines harboring biomarkers of interest are intended to effectively couple
during final targeting experiments. Ultimately, probes and antibodies are intended
to form immunoconjugates prior to targeting in order to commence multiplexing
assays with various optimized probes within a single spectral window. Thereafter, we
intend to expand to multiple spectral windows with our library and allow simultaneous
detection of several dozen biomarkers. Our final intention is to use our lifetime library
of probes in clinical settings to characterize and elucidate useful information from a
specific tumor samples in order to help develop successful personalized treatments.
2
Chapter 2
Background
2.1 Tumor Heterogeneity
While the rapid advancement of medical technology has given way to the full eradi-
cation of many diseases, such levels of containment for cancer have remained largely
elusive. In 2018, cancer was ranked as the second leading cause of death in the United
States at 1.7 million new cases and over 600 thousand fatalities [57]. While successful
detection of superficial cancer types, such as skin and breast cancers, have shown
remarkable survivability since the early 1990s peak death rate, other types, such as
pancreatic and lung, remain difficult to detect or characterize at early onset.
Optical techniques, present since the 17th century, have allowed the preparation of
histological stains and molecular detection probes to ascertain structure and function
of diseased tissue. However, the vast knowledge gained from molecular biology dur-
ing the modern era has necessitated far more molecular-level visualization, as it is
3
Figure 2.1: Normal cells progressively gain random malignant mutations, allowing
the onset of heterogeneous tumors and potential for metastasis [54].
presently well understood tumors are highly variable, even within the same patient.
This tumor microenvironment heterogeneity arises from immortalized neoplastic sub-
populations, allowed to diversify via oncogene and tumor suppressor gene mutations,
and from complex interactions between malignant cells and their neighboring cell
ecosystem to help promote proliferation, drug resistance, and drug resistance [4, 25].
Key cell types include cells derived from hierarchical differentiation of cancer stem
cells (CSCs), a rare population compromising less than 0.1% of tumor cells [51].
CSCs show substantially different therapeutic sensitivities compared to more differ-
entiated cancer cells. It therefore remains undetermined which chemotherapeutic or
radiotherapeutic agents effectively respond to this type. Endothelial cells, which may
promote nutrient delivery to growing tumors via abnormal angiogenesis, are also of
interest [40]. Inflammatory immune cells, such as myeloid suppressor cells (MDSC),
regulatory T cells (CD4 and CD8), and tumor-infiltrating macrophages (M1 or M2
phenotype), may also be classified as a key cell type [8]. Densities of cytotoxic and
memory T cells (CD3+, CD8+, and CD45RO+) are also of interest due to their
potential as a prognostic metric [48]. Additionally, the identification of key tumor
associated antigens, such as prostate cancer via PAP, PSA, and PSMA, have resulted
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in remarkable therapeutic turnarounds in recent decades [36]. Thus, there is an
outstanding need to rapidly elucidate large amounts of molecular information, which
includes the identification of key cell types, within a specific tumor microenvironment
to develop successful personalized treatments.
2.2 Molecular Diagnostics
Various molecular-level techniques have been implemented to help uncover more di-
agnostic data. This includes the current trend towards massive-scale omics, such as
genomics, proteomics, glycomics, lipidomics, and metabolomics. Methods in these
fields, such as mass spectrometry and next generation sequencing, operate via de-
struction of a large heterogeneous sample, which is then analyzed at bulk, revealing
population averages of harvested molecules of interest [55]. However, large scale anal-
ysis results in loss of structural information and molecular expression levels. Further-
more, uncommon sub-populations of markers or cells become exceedingly difficult
to identify, such as rare CSCs. Single-cell transcriptional analysis technologies at-
tempt to circumvent the exclusion of statistical outliers within a population at large
[31]. Nonetheless, spatial information within individual cells is still lost, including the
ability to predict signaling pathways, epigenetic regulation, and non-genetic variance
[38, 24, 49, 23]. As such, molecular probes are the only remaining solution to retain
spatial or molecular expression information with cellular-level resolution.
Numerous varieties of molecular targeting probes presently exist, of which the most
successful and widespread is fluorescence-based imaging. These fluorescence-based
probes, using different excitation and emission spectra, are only limited by the com-
5
Figure 2.2: The absorption spectrum of water limits biological applications of fluo-
rescent probes to wavelengths between 200 and 2000 nm wavelength [13].
bination of appropriate filter sets and total number of non-overlapping spectra given
by probes. A wide array of visible and near-infrared probes are presently available,
typically allowing for 5-10 detection channels [20]. Probes outside this region are
generally avoided due to strong water absorbance obstructing biological use [56]. Ul-
traviolet probes pose an additional tissue hazards, while far infrared probes tend to
overlap with the 10 μm thermal radiation peak of human bodies.
Other alternative molecular probes use non-fluorescent modalities for detection chan-
nels, such as surface-enhanced Raman scattering (SERS) and mass spectrometry.
SERS utilizes the coupling of plasmonic nanoparticles with reporter molecules, which
produce unique oscillations of free electrons, or fingerprints, via Raman scattering
[47]. While up to 30 channels have been estimated due to the narrow width of Ra-
man bands, in practice the complexity of spectral unmixing and the possibility of
localized heating with more probes limits SERS to approximately 10 targets [58].
Mass cytometry, in turn, utilizes rare earth metal isotope tags on samples for mass
spectrometry, demonstrating the potential of up to 32 channels via cell or tissue image
scans [2]. However, over three hours are required to scan targets at 1 μm resolution,
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comparably lower than optical techniques. While, multiplexed ion beam imaging
(MIBI) has demonstrated up to 10 channels at sub-micron resolution in breast tumor
samples, 2 scans require an hour to complete [1]. Aside from long scan durations,
mass spectrometry systems also require the destruction of a sample, preventing any
further analyses, and are often quite complex and expensive. Thus, there is a need to
develop a molecular diagnostic platform with similar simplicity, speed, and specificity
as spectral fluorescence imaging.
2.3 Fluorescence Lifetime Imaging Microscopy
An exciting expansion to conventional fluorescence imaging incorporates the use of
fluorescence lifetime imaging microscopy (FLIM) as a second dimension of detec-
tion channels. Fluorescence lifetime is defined as the intrinsic duration a fluorescent
species remains in its excited state before emitting a photon, determined from both
radiative and non-radiative processes as energy dissipates from the molecule to the
ground state [30]. While organic fluorophores generally retain lifetimes between 0.5 -
4 nanoseconds (ns), other fluorescent species, such as long-lifetime dyes or semicon-
ductor nanoparticles (quantum dots) may exhibit lifetimes in the range of 10 - 100
ns. FLIM is of interest since multiple species can share the same overlapping spectra
but exhibit distinct fluorescence lifetimes.
2.3.1 Curve Fitting Decay Half-Lives
Conventionally, lifetime is quantified by curve fitting a decay half-life for a population
[20]. Using a short excitation pulse, an intrinsic decay composed of N fluorescent
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species can be modeled by Eqn. (2.1).
Iˆ(t) = Iˆ(0)
N∑
i=1
αie
−t /τi (2.1)
Iˆ(0) is the number of instantly emitted photons at time zero, αi is the amplitude, and
τi is the fluorescence decay time of the i -th species [7, 17]. The amplitude-weighted
lifetime, τa (or the apparent lifetime), is typically used to determine energy transfer
efficiency. The average lifetime 〈τ〉 contains f, the fractional contribution of the i -th
species to the total intensity.
τa =
N∑
i=1
αiτi 〈τ〉 =
N∑
i=1
fiτi fi = (αiτ)/τa (2.2)
Finally, the measured decay I (t) is simply a convolution of the intrinsic decay and
the instrument response function (IRF ) plus any background noise in the system n(t)
shown in Eqn. (2.3).
I(t) = IRF ⊗ Iˆ(t) + n(t) = IRF ⊗
{
Iˆ(0)
N∑
i=1
αie
−t /τi
}
+ n(t) (2.3)
FLIM can be conducted in either the time or frequency domains, which involves
measurements of scattered excited light or the use of a fluorescence lifetime standard
of known lifetime to calibrate the IRF in one-photon excitation, respectively.
Most FLIM analysis methods curve fit measured data, often via an iteratively con-
strained optimization algorithm to estimate parameters α and τ [44, 16]. Each it-
eration compares parameters to measured data, which provides feedback for further
optimizing the model. Non-linear least squares estimation is the current analysis
method of choice for both time and frequency domains. First, a simple decay model,
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usually a single exponential decay, is used to make initial guesses to parameters.
Normally, a chi-square value is used to examine the computer algorithm fit, and if
rejected, a more complicated decay model is used, typically adding another exponent.
Often, this process is quite complex, largely due to low photon counts in real systems.
As such, no universal method has been established to accept or reject models and
an expertise level of physics is required, in which the validity of the statistical tools
are debatable. Presently, no more than 3 exogenous probes have been resolved using
curve fitting of decay half-lives.
2.3.2 The Phasor Approach
The phasor approach to FLIM, pioneered by Gratton et al. in 2008, offers an elegant
solution to alleviate the issues with curve fitting decay half-lives by transferring data
into the frequency domain and graphing onto a polar plot [12, 45]. A decay trace
I (t) is measured at each pixel location and subsequently plotted as a phasor, drawn
as a semicircle curve centered at (G = 0.5, S = 0.5) with radius 0.5, by applying sine
and cosine transforms equivalent to the real and imaginary components of a Fourier
transform shown in Eqns. (2.4).
g(ω) =
∫∞
0
I(t)cos(ωt)∫∞
0
I(t)
s(ω) =
∫∞
0
I(t)sin(ωt)∫∞
0
I(t)
(2.4)
After calibration of the phasor plot to a known decay trace, by solving integrals for
Eqns. (2.4), the following equations are produced to give a direct relationship between
a set of phasor positions and their corresponding lifetimes.
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Figure 2.3: Mapping frequency and time domain FLIM data on the phasor plot [32].
g =
N∑
i=1
fi
1 + ω2τ 2i
s =
N∑
i=1
fiωτi
1 + ω2τ 2i
(2.5)
In the condition of a single-lifetime fluorescent species, these equations reduce to fol-
low direction relationships shown in Eqns. (2.6). While single-lifetime species are
plotted directly onto the semicircle arc, complex multiple-lifetime species are decom-
posed as a linear combination of multiple phasors, and appear within the semicircle.
g =
1
1 + ω2τ 2
s =
ωτ
1 + ω2τ 2
τ =
1
ω
(
s
g
)
(2.6)
The power of the phasor approach stems from its ability to act as a quantitative ruler
measuring both single-lifetime and complex lifetime species. The plot can also be
shifted to center on a specific lifetime foci by using different modulation frequencies
(i.e at 80 MHz the top of the semicircle lies at 2 ns, or 8 ns for 20 MHz). Positions to
10
Figure 2.4: Linear unmixing of multiple fluorescent species on the phasor plot [32].
the far right approach a lifetime of zero, while those to the far left approach an infinite
lifetime. In mixtures, the distance between two component species is proportional
to the fractional contribution of each species, allowing for quantitative analyses of
constituents. Three or more species will produce a theoretical polygon in which the
signal mixture may appear (Fig. 2.4).
2.3.3 FLIM Phasor Applications
The phasor approach to FLIM can also qualitatively analyze fluorescence quenching in
systems, including Fo¨rster resonance energy transfer (FRET), Dexter electron trans-
fer, and dark quenching. FRET is defined as non-radiative energy transfer between
an excited molecule and donor molecule via dipole-dipole interactions at distances
less than 10 nm, and has been extensively studied with the phasor approach for the
past decade [14, 28].
Short-distance quenching effects between two fluorescent species of the same kind
(homo-quenching) or different kind (hetero-quenching) in a donor-acceptor pair in-
11
Figure 2.5: Analyses of FRET trajectories with the phasor plot [32].
teraction are of particular interest. Either two fluorescent species can be used together
as a donor-acceptor pair, or a dark quenching dye can act as an acceptor. Unlike a
fluorescent acceptor, a dark quencher absorbs energy and emits it as heat [6]. Any
significant quenching effect produced by an acceptor molecule will also change the
lifetime of the donor-acceptor pair compared to a donor-only sample. This effect can
also be visually seen on the phasor plot (Fig. 2.5). Coupling of quantum dots and
quenchers have been further shown to accelerate lifetime, highly dependent on dose.
Since the advent of the phasor approach to FLIM, over 10 cellular autofluorescent
species have been identified in distinct locations on the phasor plot [52]. This approach
has also seen success in studying cellular metabolism, the endomembrane system,
and cancer malignancy [15, 29, 41]. Nonetheless, the full potential of the phasor
approach has not yet been realized, as no exogenous probes have been developed
incorporating the extra dimension of FLIM to couple with conventional fluorescence
spectral imaging due to the limitations of curve fitting decay half-lives.
The phasor approach provides the potential to create the first fully functional lifetime
probe library. Such a lifetime library would need to be developed from a wide array
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of fluorescent species encompassing both the full range of wavelengths used in fluores-
cence spectral imaging (such as the Alexa Fluor series) and a large range of different
fluorescence lifetimes for each spectral window (0.5 - 50 ns). Using 8 different spectral
detection channels, each with 10 distinct-lifetime fluorescent species, up to 80 unique
probes and detection channels may be created. This project will demonstrate the
construction of a lifetime probe library using fluorescent nanomaterials encapsulated
within silica, each distinctly resolved using the phasor approach to FLIM, within the
context of tumor characterization via biomarker targeting.
13
Chapter 3
Synthesis
To begin construction of our library of probes, we first sought to produce a probe
core encapsulating mixtures of fluorescent species at specific loading ratios. Numerous
nanomaterials have been used to transport reporter molecules or therapeutic agents
in a wide array of medical applications, with varying degrees of success, such as
iron oxide crystals, gold nanorods, and polymer liposomes or micelles [22]. For our
probe cores, amorphous silica was selected due to existing simple synthesis protocols,
low toxicity, unhindered fluorescence of encapsulated species, and feasibility for easy
surface modifications via triethoxy silane molecules [37, 39].
3.1 Reverse Microemulsions
The sol-gel process, commonly used by material scientists, incorporates small precur-
sor molecules to form a larger object, often in the form of polymerous gels [10]. In
1968, Werner Sto¨ber first pioneered the highly popular adaptation of this process to
14
Figure 3.1: Hydrolysis and condensation of TEOS in the Sto¨ber Process.
synthesize silica nanoparticles, now known as the Sto¨ber process [50]. The precursor
molecule, tetraethylorthosilicate (TEOS), is hydrolyzed with water, in the presence
of ammonia as a catalyst, and allowed to form larger structures via condensation with
other TEOS molecules (Fig. 3.1). Variations of the Sto¨ber process have been able to
produce solid core probes, shell-core probes, hollow shells, mesoporous probes, and
other nanomaterials.
Si(OEt)4 + H2O → Si(OEt)3OH + EtOH
2Si(OEt)3OH → (EtO)3Si-O-Si(OEt)3 + H2O
The Haun group previously experimented with different renditions of this process, and
ultimately selected synthesis of silica via reverse microemulsions [34]. This adaption
has been optimized to use 1.3 mL of IGEPAL-CO520 surfactant to produce water-in-
oil drops within 10 mL of cyclohexane. Organic fluorescent dyes, dark quencher dyes,
or hydrophobic quantum dots of interest are subsequently added. 150 μL ammonium
hydroxide (30% in water) is added to form droplet interiors. Finally, 80 μL of TEOS is
15
Figure 3.2: Mixtures of triethoxy silane and TEOS will form hollow or porous silica
in reverse microemulsions. Presence of only TEOS forms solid silica cores [33].
added and allowed to react for 24 hours to produce silica particle cores (see Appendix
A.1 for protocol). Gradually, fluorescent species are shuttled into the drop interior
and embedded within a silica mesh.
In order for either organic fluorescent dyes or dark quencher dyes to successfully
incorporate into the particle interior, both must be purchased or premodified with
an N-Hydroxysuccinimide (NHS) leaving group. These dyes, stored in dimethylfor-
mamide (DMF), are then reacted with (3-aminopropyl)triethoxy silane (APTS) for
24 hours in ethanol (Fig. 3.3). APTS, a triethoxy silane, retains a structure similar
to TEOS, with one of four ethoxy chains replaced by a propyl chain terminating in a
primary amine. The remaining three ethoxy chains can be used to react with TEOS
for incorporation into the silica probe.
Fluorescent semiconductor nanoparticles, known as quantum dots, are particularly
exciting for exhibiting broad absorption bands, narrow emission peaks, size-tunable
emission spectra, and long fluorescence lifetimes. Large quantum dots premodified
with hydrophobic surface ligands can be directly added to the synthesis reaction with-
out any additional modifications, due to a TEOS transfer mechanism which shuttles
hydrophobic quantum dots into the hydrophilic drop interior [27].
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Figure 3.3: Dyes labeled with NHS leaving groups will form amide bonds with primary
amine reagents, specifically a triethoxy silane [19].
To help populate numerous different positions on the phasor plot of a single emission
window (initially yellow-orange), two additional projects in the Haun Group incor-
porate an exploratory array of quantum dots and fluorescent dyes, respectively, from
various vendors. Fluorescent dyes tested include Alexa Fluor 555, BODIPY TMR-X,
and Rhodamine from Thermo Fisher, and KU530 from KU Dyes. Quantum dots from
Invitrogen, NN-Labs, Ocean NanoTech, and Strem have also been tested, which in-
clude both spheres and rods, and cores made from cadmium selenide, copper indium
sulfide, indium phosphide, and manganese-doped zinc sulfide. Additionally, mixtures
of fluorescent dyes or quantum dots and dark quenchers, namely QXL 570 and QXL
610 from Anaspec, have been tested. The remainder of this project uses silica probes
encapsulating quantum dots as a basis for testing further modifications.
3.2 Surface Silanization
Much like APTS, other triethoxy silane molecules may be added after 24 hours of
core synthesis to functionalize surfaces for further modifications. To remove unreacted
material and allow the transfer of probes into aqueous solution, particles are washed
via four rounds of centrifugation to produce a pellet, supernatant disposal, and pellet
resuspension, via ethanol as an intermediate solvent.
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Once washed, particles may be either directly analyzed or undergo further modifi-
cation via covalent addition of molecules to surface functional groups. Our typical
analyses use dynamic light scattering (DLS) to determine probe size via a Malvern
Zetasizer Nano DLS system, absorption spectroscopy with a Cary-60 instrument, flu-
orometry with a Cary Eclipse instrument, scanning electron microscopy (SEM) with
a FEI Magellan 400 XHR system, transmission electron microscopy (TEM) with via
a FEI-Philips CM20, or the phasor approach using a custom-built FLIM system and
software (SimFCS) developed by the Laboratory for Fluorescence Dynamics at the
University of California, Irvine.
An example of SEM, phasor, yield, and DLS results of quantum dots within silica
probes are shown in figure 3.4. Increasing volumes of QXL dark quencher dyes were
loaded into probe cores to unlock distinct phasor positions, shown in (C). Of par-
ticular note, additional modifications to particle surfaces have no effect on phasor
plot position. Unless specifically stated, the remainder of this project will display
results of silica probes incorporating CZ quantum dots with core-shell architecture,
cadmium selenide and zinc sulfide respectively, from NN-Labs. These quantum dots
were specifically chosen for retaining a bright 590 nm emission peak, low price, high
concentration, and hydrophobic octadecylamine stabilizing surface ligands.
Along with determining the appropriate silica probe architecture for co-encapsulating
mixtures of fluorescent species, work previously done in the Haun Group determined
the appropriate reagent quantities during core probe synthesis, but left particles either
with no surface silanization (terminating in ethoxy chains) or modified with APTS.
Both a lack of surface silanization and the addition of APTS were unable to disperse
probes in water or PBS, and produced large aggregates.
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Figure 3.4: CZ Probes analyzed with (A) SEM, (B) phasor approach at two different
excitations, (C) phasor approach with increasing amounts of quencher, and (D-E) flu-
orometry and absorbance spectroscopy to calculate PQY. (F) DLS results of different
surface silane ratios.
To help alleviate probe aggregation, carboxyethylsilanetriol (CEST) from Gelest
and 3-(trihydroxysilyl)propyl methylphosphonate (TPMP) from Sigma Aldrich were
added to particle surfaces at different molar ratios. Carboxylic acid was specifically
chosen as the base for future modifications via carbodiimide crosslinking (full details
in section 4.1), while phosphonate groups should help prevent aggregate formation
and render efficient aqueous dissolution. The effectiveness of aqueous dissolution
necessitated the use of filtered centrifuge tubes for washing all further modifications
discussed in chapter 4 instead of pelleting particles via the typical post-synthesis wash
protocol. With these functional groups, probe cores were able to produce consistent
DLS results of 40 nm. A 1:1 molar ratio of CEST:TPMP was selected as most viable,
and is used for the remainder of this project.
The density of silicon atoms on the surface of each synthesized probe, at an estimated
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1:1 ratio of quantum dots to silica probes, was used as the basis for further estimates
[21]. Assuming an excess of surface silanes, an estimated 33,000 functional groups
were present on probe surfaces, of which 17,500 were carboxylic acid moieties (see
Appendix B.2 for calculation). Initially, 30 μL of total silane was arbitrarily added to
surfaces (20 μL CEST, 10 μL TPMP). However, these calculations also determined
a 60-fold excess of surface silane was added to reactions, and was later suspected as
hindering early modifications (see section 3.3).
To illustrate this, an assay of probes was prepared using different amounts of total
surface silane while still retaining a 1:1 CEST:TPMP molar ratio (DLS results shown
below). Select samples were imaged under SEM which revealed a large 300 μL excess
of total surface silane created smooth-surface 200 nm structures. Surprisingly, the
high energy electron beam decomposed these structures over the course of several
minutes (Fig. 3.5), allowing silica probes trapped in excess silane to become visibly
discernible. Ultimately, it was determined a large excess was detrimental for synthesis.
The remainder of this project uses particles modified with a total of 3 μL of surface
silane (2 μL CEST, 1 μL TPMP).
3.3 Encapsulation Optimization
Initially, Qdot 585 ITKs, bright core-shell organic quantum dots (CdSe/ZnS) from
Invitrogen, were used for early syntheses and modifications. However, calculations
used to determine the total number of silica probes in a standard synthesis revealed
there should more probes than quantum dots, by an order of magnitude (see Appendix
B.1 for calculation). This illustrated the vast majority of our probes should be void of
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Figure 3.5: Variation of total surface silane at 1:1 CEST:TPMP molar ratio. Analyzed
with (A) DLS. (B-E) SEM timelapse of 300 μL total silane taken 1 minute apart.
quantum dots and composed entirely of silica. To test this, silica probes encapsulating
Invitrogen quantum dots were imaged using TEM (Fig. 3.6). As predicted, by loading
100 μL of quantum dots into the synthesis reaction only 10-15% of silica probes were
found to have any discernible quantum dots.
To compensate for this, experiments were conducted to decrease the proportional
ratios of all other reagents during a synthesis, allowing for a higher concentration
of quantum dots (5x, 10x, and 20x more concentrated). However, both size results
and TEM images revealed silica probes became substantially smaller, and irreversibly
aggegrated together. We believe the proportionally larger amount of decane solution
quantum dots are inherently in, disrupt the reverse microemulsion synthesis.
While a side project went on to explore alternative approaches to efficiently use
Invitrogen quantum dots in probes, the primary quantum dot of focus was switched to
the comparatively inexpensive and 5x more concentrated CZ particle from NN-Labs.
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Figure 3.6: Concentration of 100 μL Invitrogen QDs via proportionally increasing all
other synthesis reagents. Analyzed with (A) DLS and (B-E) TEM. Note the vast
majority of silica probes have no visible QDs in (B).
Figure 3.7: Determination of 1:1 QD:Probe ratio using CZ QDs at (A) 100 μL, (B)
150 μL, and (C) 200 μL.
An assay of different synthesis loading volumes was used to determine the appropriate
1:1 ratio of quantum dots to silica probes (Fig. 3.7), which visually estimated 200
μL of CZ particles would be enough to fill most probes. Note that some silica probes
appear to be smaller and have no encapsulated quantum dots, while others appear
to have multiple. For the remainder of this project, all modifications and targeting
experiments employ 200 μL of CZ quantum dots from NN-Labs.
It should be noted that this metric is simply an estimate for standardizing later
experiments. Furthermore, based on assays conducted with increasing amounts of
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Figure 3.8: Detection of large crystal structures post-synthesis via (A) DLS and in
SEM with a (B) 6 month and (C) 2 week old samples.
CZ quantum dots, the phasor position did not shift from homo-quenching effects,
indicating subtle differences in our quantum dot loading volumes have no significant
effect on phasor results. Molar concentrations given by NN-Labs indicate 6.0 ∗ 1014
quantum dots should be present during core synthesis, and here, we assume for all
future modifications and targeting that an equivalent amount of probes is produced,
given the estimated 1:1 ratio.
Of particular interest, both DLS and SEM results (Fig. 3.8) occasionally indicate
the presence of large crystalline structures, post-synthesis. These structures continue
to appear in later modifications and targeting, indicating probes have either aggre-
gated together during synthesis or crystals gradually formed within the TEOS stock
solution. DLS results of the stock solution have alluded to the latter explanation.
In either case, a significant amount of probes, and silica precursor, could be lost to
these structures. Section 5.3 provides a solution for removal of these structures via
size exclusion chromatography (SEC).
Recently, a NanoSight system from Malvern was installed at the University of Cali-
fornia, Irvine. Future experiments will attempt to gain a higher precision of the total
number of silica probes produced from reverse microemulsion synthesis.
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Chapter 4
Modifications
Despite the high level of aqueous dissolution instilled by carboxylic acid and phos-
phonate surface moieties, timescales of several weeks to months have shown probes
precipitate out of solution at concentrations of 90 nM. Furthermore, unmodified silica
probes are known to adhere to glass surfaces, hindering cell targeting assays with con-
ventional glass slides. Thus, direct conjugation of an antibody to probe will not result
in successful targeting, and must first undergo modification with protective molecules.
Short linkers could then be covalently reacted onto the ends of these molecules to act
as a bridge to an antibody of interest.
4.1 Primary PEGylation
While protective molecules are used to encapsulate probe core for various purposes
(such as biomarker targeting, blood transport, membrane fusion, etc), most probes
must first successfully arrive at a location of interest, often in aqueous solution [53].
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Figure 4.1: Carbodiimide EDC crosslinks amines and carboxylic acids to form an
amide bond. Addition of NHS (bottom-most pathway) increases efficiency [19].
As a result, one of the most popular protective molecules is polyethylene glycol (PEG)
due to its biocompatibility, immunocompatibility, and hydrophilic nature [5, 35].
Amine-terminating PEG chains may be conjugated onto carboxylic acid moieties via
carbodiimide crosslinking using N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hy-
drochloride (EDC) and NHS (Fig. 4.1). In the presence of EDC crosslinker, carboxylic
acid groups will temporarily form an o-Acylisourea intermediate group. However, this
product is highly unstable and will rapidly hydrolyze and revert back into a carboxylic
acid. NHS is instead added to help form a dry stable intermediate, replacing EDC,
to become a favorable leaving group in the presence of a primary amine and form an
amide bond.
To help drive the reaction, a molar excess of EDC and NHS was selected, in compar-
ison to PEG. When reacted for 3 hours, favorable results have been produced with
a 10x excess of EDC and a 3x excess of NHS, specifically chosen for the multiple
reaction pathways EDC may take. While our own calculations had predicted 6.55
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silane groups could be loaded onto a square nanometer on a silica probe, Dai et al.
had previously determined approximately 6 PEG molecules may occupy a nm2 on a
probe surface [9]. Assuming a molar excess, the theoretical basis of 6 PEG chains per
nm2 was used to determine a 40 nm probe may have up to 30,000 PEG chains on its
surface (see Appendix B.2 for calculation).
Synthesized probes in water were used as two-thirds of the total volume in PEG
reactions. Stock solutions for EDC and NHS, purchased from Sigma Aldrich and
stored dry, were diluted in water immediately before usage. Azido-PEG35-amine
(AzPEG) and methoxy-PEG36-amine (mPEG36), purchased from BroadPharm and
stored in DMF, were used for all PEG reactions at various ratios. Azide moieties
were specifically selected for future linker attachments (detailed in section 4.3), while
mPEGs act as nonreactive hydrophilic filler chains (see Appendix A.2 for protocol).
Long AzPEG and mPEG chains, 15 nm in size, allow a maximum addition of 30 nm
to probe sizes if fully extended via brush configuration of the PEG corona. Thus,
fully PEGylated probes should retain sizes of 60-70 nm (Fig. 4.3).
4.2 Backfill PEGylation
Research conducted by Dai et. al had previously determined low-density PEGylated
probes used for in-vivo targeting have the tendency to adsorb smaller proteins between
PEG chains. [9]. As part of the innate immune system, these proteins subsequently
recruit larger proteins to engulf probes via formation of a large protein corona, ulti-
mately rendering probes as ineffective targeting agents. Simply increasing the density
of PEG molecules will prevent the adsorption of proteins, however, surface crowding
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Figure 4.2: Probes undergo either primary PEGylation with long Az-PEG35-amine
and mPEG36-amine chains, or additional backfill PEGylation with short mPEG12-
amine chains. MeTz-DBCO linkers are added as a final modification at azide moieties.
will also hinder the binding efficiency of specific functional groups on the termini of
PEG chains.
To circumvent these issues, a second ”backfill” PEGylation reaction can be performed
on probes, using much smaller and more numerous filler chains. We were particularly
interested if the reported effects of backfilled PEG chains would produce favorable
binding to cell surfaces and prevent particle adsorption to glass surfaces.
Specifically, we opted for mPEG12-amine, purchased from BroadPharm, for backfill
modifications. 90% of PEG chains added were shorter mPEG12 chains, while the
remaining 10% were one of a select ratio of mPEG36 and AzPEG. Backfilled probes
underwent a second 3 hour PEGylation reaction, still retaining a 10x molar excess of
EDC and 3x excess of NHS.
Of note, higher densities of mPEG on a surface appear to force the PEG corona
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Figure 4.3: DLS results at different loading ratios of (A) long mPEG36 chains, (B)
AzPEG and mPEG36, (C) AzPEG and mPEG36 with 9:1 mixture of backfilled
mPEG12 to total PEG, and (D) MeTz-DBCO added at a 3x molar excess.
into an extended brush configuration. However, higher densities of AzPEG appear to
decrease the size of the corona. This effect might be due to the greater hydrophobic
nature of azide moieties.
4.3 Click Chemistry Linkers
Before probes can be bound to antibodies, appropriate pairs of linkers must be added
to probe exteriors and antibodies. While creation of immunoconjugates (ICs) prior
to targeting is the ultimate intention of our probe system, the process of creating ICs
require an additional series of steps including size exclusion chromatography (SEC)
featured in section 5.3. To facilitate this process, a two-step targeting approach was
initially selected for proof of concept. This method first allows modified antibodies
to react to biomarkers of interest on tumor cells, and is followed by the addition of
fully functionalized silica probes.
To employ the successful use of two-step targeting within a biological system, reac-
tive moieties between probes and modified antibodies must be highly specific to one
another with minimal side reactions. As such, bioorthogonal reactions, which use
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Figure 4.4: Popular bioorthogonal reactions using Diels-Alder mechanisms [43].
chemistry not conventionally found within biological systems, are of interest. A wide
array of click chemistry linkers have been extensively studied for these purposes over
the last two decades. Ideally, reactions between linkers should also occur rapidly in
biological conditions (i.e pH and temperature), limiting the production of toxic and
non-toxic byproducts [43]. The table below details a list of popular bioorthogonal
reaction schemes.
Of particular note is the extremely fast reaction rate of trans-cyclooctene (TCO) and
tetrazine, which employs an inverse-electron-demand Diels-Alder cycloaddition and
has allowed for its extensive use in live cell imaging in-vitro and in-vivo [11, 46].
However, the instability of tetrazine over prolonged time scales necessitates use of
its more stable methyltetrazine (MeTz) analog in our primary two-step coupling,
characterized by a reaction rate constant of 880 M−1 s−1 [26]. For our primary probe
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Figure 4.5: Popular bioorthogonal reactions with corresponding reaction rates and
additional comments [43].
to antibody reaction, we terminated silica probes with MeTz and modified antibodies
with TCO (detailed in section 5.1).
Before the primary MeTz to TCO coupling could commence, MeTz moieties need
first undergo conjugation onto probe termini. Specifically, this required modifica-
tion of azido groups on AzPEG chains with a small molecule carrying MeTz. 4-
Dibenzocyclooctynol (DBCO) was chosen as the appropriate molecule to couple with
the azido group via the slower Az-DBCO reaction. MeTz-DBCO, purchased from
Click Chemistry Tools (shown below), was allowed to react for 24 hours with Az-
probes in the presence of DMF and subsequently washed using filtered centrifugation
tubes (see Appendix A.3 for protocol). A 3x molar excess of MeTz to AzPEG chains
per silica probe was used for all remaining studies.
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Figure 4.6: Azide to BCN coupling. CF488A-BCN dye was conjugated onto probe
exteriors and centrifuge filter washed prior to absorbance spectrometry.
Of particular note, DLS results taken after the addition of MeTz show backfilled
probes seem smaller than their counterparts before the addition of MeTz (Fig. 4.3).
This might be due to the hydrophobic nature of tetrazine, which could collapse PEG
coronas and shield itself even in backfilled conditions.
Prior to Az-DBCO coupling, we tested whether azido groups were both present and
exposed via a 1,3-dipolar Huisgen cycloaddition reaction with CF488A-BCN fluores-
cent labels (Fig. 4.6). After filtered centrifugation tube washes, a strong green-blue
color persisted and absorption data revealed the presence of a peak at 488 nm, cor-
responding with the CF488A dye absorption peak.
After Az-DBCO coupling, we tested whether probes were successfully terminated in
MeTz. Cy5-TCO purchased from Click Chemistry Tools, was reacted to probe ex-
teriors via the MeTz-TCO reaction for an hour in the presence of DMF. Subsequent
washes via filtered centrifugation tubes produced probes with purple hue, character-
istic of Cy5 emission.
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These results illustrate silica probes were succcesfully modified and terminated with
azido groups on PEG chains, followed by MeTz groups, and were ready to proceed
with biomarker targeting. To recap, fully functionalized 40 nm silica probes en-
capsulated fluorescent species of interest. Silica cores were surrounded by a large
PEG corona, comprising entirely of long PEG chains or a combination of long and
short backfilled PEG chains. PEGylated probe exteriors terminated in exposed MeTz
groups to allow subsequent conjugation onto a TCO-antibody in order to target tumor
biomarkers of interest.
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Chapter 5
Targeting
Upon complete functionalization, finalized MeTz-probes were ready to commence
targeting trials. This was initially conducted via two-step targeting of TCO-modified
antibodies onto cell surfaces, followed by addition of probes without backfill, and later
by backfilled probes. Lastly, ICs were formed by direct conjugation of antibodies and
probes together, followed by direct cell targeting as a single unit. ICs also necessitated
SEC to remove aggregates or other large structures from final solutions.
5.1 Bioconjugate Preparation
Three elements are required for two-step targeting; finalized probes, modified anti-
bodies, and cells with a biomarker of interest. To match MeTz termini on probes,
appropriate antibodies must be modified with TCO. Among the commonly available
amino acid side chains, primary amines on lysine remain the most popular target for
antibody modifications [3]. For this specific reaction, the NHS ester to primary amine
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Figure 5.1: During two-step targeting, TCO-modified antibodies first target a select
biomarker and are subsequently labeled by a Tz-probe.
reaction from section 3.1 was employed, previously used to couple dye to triethoxy
silanes for probe incorporation. TCO-NHS ester, purchased from Click Chemistry
Tools, was used for these reactions.
Previous investigations by the Haun Group found TCO groups were often buried
within antibodies and inactive, which may be alleviated by using high levels of bovine
serum albumin (BSA) in solution [42]. A second method involves conjugating PEG
chains onto antibodies via the carbodiimide crosslinker reaction used in section 4.1.
For antibody-probe bioconjugation, we employed the use of both TCO linkers directly
conjugated to antibodies and TCO-terminated PEGylated antibodies.
For targeting studies, breast cancer cell lines, MCF-7 and SKBR3, were specifically
chosen for overexpressing epithelial cell adhesion molecule (EpCAM) and human epi-
dermal growth factor receptor 2 (HER2), respectively. Corresponding antibodies,
anti-EpCAM (aEpCAM) and anti-HER2 (aHER2), were purchased from ConjuProbe,
modified with TCO or PEG8-TCO, and analyzed with a NanoDrop 2000 system to
ensure appropriate concentration.
TCO-NHS ester, stored in DMF, in the presence of phosphate buffered silane (PBS)
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and BSA (as PBS+) was used to modify select antibodies at primary amine termini
during a 1 hour reaction (see Appendix A.4 for protocol). Alternatively, COOH-
PEG8-amine chains, purchased from Click Chemistry Tools, were modified via TCO-
NHS to produce COOH-PEG8-TCO, and subsequently coupled to amine termini on
antibodies via carbodiimide crosslinking for 3 hours in the presence of NHS and EDC.
Fully modified antibodies were stored at 4 C until used for targeting.
5.2 Two-Step Targeting
To commence two-step targeting, tumor cell lines of interest were allowed to grow in
cell culture flasks until an appropriate passage number and placed in 8 well borosil-
icate chamber slides via established American Type Culture Company (ATCC) cul-
ture protocols. Cells were allowed to adhere to well plate bottoms and proliferate
for another 1-2 days within 500 μL the appropriate culture media as specified by
the ATCC. For two-step targeting, media was carefully aspirated out of wells, and
followed by three PBS+ washes and aspiration cycles to clear out suspended cellular
debris. Modified TCO-antibodies, stored in PBS, were then added to well plates at 10
μg/mL and allowed to attach to biomarkers for 30 minutes. Three additional PBS+
washes followed before the addition of MeTz-Probes at variable nM concentrations,
and allowed to react for 1 hour. Three final PBS+ wash cycles were used to remove
non-adhered probes and placed in 150 μL of PBS+ (see Appendix A.5 for protocol).
For the first set of targeting experiments, MeTz-probes with only the addition of
long PEG chains at varying ratios of AzPEG densities were used. Phasor plot results
(Fig. 5.2), illustrate several control and positive conditions at different AzPEG surface
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Figure 5.2: Long PEG-modified MeTz-terminated CZ probes targeted onto HER2 in
the presence of antibody (positive) and no antibody (control), at different AzPEG
densities with probe-only and cell-only controls.
densities. For all experiments shown, probes are excited with a 438 nm excitation
laser and imaged in the 560-660 emission window.
While the probes-only control features probes in aqueous solution on a glass slide,
the cells-only control features cells adhered to glass on the bottom of a well. Due to
various autofluorescent species naturally existing within cells (i.e. NADH and FAD),
the cell-only position on the phasor plot corresponds with this intrinsic combination
of lifetimes for a given cell type. The 0% AzPEG control features probes that contain
no AzPEG, nor any MeTz, and thus lack the ability to specifically bind to antibodies.
The remainder of the conditions specify the percent of AzPEG groups compared to
total long PEG molecules, which directly correlates with the assumption that one
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MeTz molecule was able to bind to a probe for every AzPEG chain. For all variable
AzPEG percentages, both a control condition (without any antibody) and a positive
condition (with antibody) were tested. Phasor plots contain insets of cell fluorescence
images and FLIM images using the phasor approach to generate heat maps of cells.
Phasor positions of no-antibody controls and antibody positives largely correspond
with the expected location of probes that were able to successfully bind to biomarkers.
However, large aggregate structures are clearly visible in image insets, alongside large
prominent tails across phasor plots. This indicates that some level of non-specific
targeting, possibly due to aggregates, is present in solution mixtures prior to cell
targeting experiments. To circumvent these issues, we subsequently used backfilled
MeTz-probes at various densities of long AzPEG (Fig. 5.3).
The phasor plots for these conditions also illustrate similar control and positive results
as MeTz-probes with only long PEG chains. Of note, every condition with silica
probes produced large amounts of visible aggregates or non-specific binding to glass
surfaces. This is further exemplified by similar phasor plots between no-antibody
and antibody conditions, indicating PBS wash cycles were not sufficient to remove
silica probes from glass slides. The failure of backfilled probes to perform as well as
non-backfilled probes might possibly be due to nanoscale imperfections on glass slides
which could trap particles due to the differential lengths in PEG chains.
5.3 Immunoconjugation
A potential method to prevent adherence of backfilled probes to glass surfaces could
involve an assay of probes modified with different ratios of long PEG to short PEG,
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Figure 5.3: Backfilled MeTz-terminated CZ probes targeted onto EpCAM in the pres-
ence of antibody (positive) and no antibody (control), at different AzPEG densities
with probe-only and cell-only controls.
as our own backfilled modifications have only used a 9:1 ratio. However, this might
still not prevent significant aggregation as probes with only long PEG also retained
high levels to non-specific binding of large structures. To help circumvent aggregates
in our final solutions, ICs were created specifically for allowing SEC to occur after
MeTz-TCO coupling. Both types of PEGylated probes, with and without backfilled
PEG chains, were conjugated onto antibodies of interest, size-separated through liquid
chromatography, and targeted onto biomarkers of interest.
A 4x molar excess of TCO-antibodies were allowed to react with MeTz-probes for 1
hour in the presence of PBS in aqueous solution (see Appendix A.6 for full protocol).
After reacting, ICs in PBS solution were filtered through an AKTA pure size exclu-
sion liquid chromatography system connected to an XK 16/40 column packed with
Sephacryl S-500 HR resin, purchased from GE Healthcare.
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Figure 5.4: (A-B) 50 μm porous beads readily internalize small particles via diffusion.
(C-D) Larger particles avoid entry into beads and emerge first from column, while
smaller particles emerge later based on size [18].
Initially, particle recovery via fluorometry indicated over 99.9% of probes passed
through the column were lost. The high concentration, containing quantum dots,
visibly stained the top of the column an orange hue, indicating probes in PBS solu-
tion had failed to pass through. Likewise, fluorometry reported over 99.9% of probes
had been lost. Unexpectedly however, during column-washing in water after the
main filtration and collection sequence, the orange stain disappeared and was sent
into waste. This indicated probes in water could pass through a column instead of in
PBS.
The stability of probes in different solvents was subsequently tested. In the presence
of water particles were stable. However, PBS and PBS+ (PBS and BSA protein) so-
lutions caused irreversible aggregation and sedimentation of particles. We proceeded
to compare the stability of particle cores terminated in CEST, TPMP, and a mixture
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of CEST and TPMP. Unexpectedly, the CEST-only condition remained stable in all
solvents. With the addition of mPEG to CEST-terminated probe cores, probes re-
mained stable in water and PBS+, but still produced large levels of sedimentation in
the presence of PBS.
The stability of CEST cores in PBS, when compared to CEST cores modified with
mPEG indicates the cohesive repulsion of CEST is masked by mPEG on probes. The
known stability of mPEG chains in aqueous and ionic solutions dictates this should
not occur if no other destabilizing agents were present. We believe the reason for this
instability might be due to residual surfactant left over from reaction synthesis that
continues to coat probe surfaces. The removal of this surfactant via incineration of
probes at high temperature is a possible way to circumvent this issue. An alternative
strategy could include the addition of anionic moieties to PEG chains to help prevent
probe aggregation. Thereafter, SEC after immunoconjugation could remove aggre-
gates and promote efficient targeting of biomarkers when analyzed with the phasor
approach to FLIM.
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Chapter 6
Summary
Tumor heterogeneity has necessitated creation of biomarker detection platforms which
can characterize complex microenvironments to help develop successful personalized
treatments. However, current large-scale analytical methods typically destroy sam-
ples, thereby causing the loss of spatial information and the identification of rare key
cell types, which exhibit critical roles in cancer progression. Fluorescent probes may
be used to extract this information, however, current libraries retain limits of 5-10
detection channels and alternative probe systems are exceedingly expensive or time-
consuming for practical clinical settings. The phasor approach to FLIM has recently
provided the potential to expand upon conventional fluorescence imaging by adding
an extra dimension of detection channels, but has not yet reached its full potential
due to the lack of an existing lifetime probe library.
Here, we have demonstrated the preliminary construction of a lifetime library of
probes using silica to encapsulate a controlled mixture of fluorescent species via re-
verse microemulsion synthesis. Incorporated agents include hydrophobic quantum
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dots transferred into probe interiors, and either organic fluorescent or dark quenching
dyes, integrated into probe cores. These mixtures have been used to unlock a wide
array of phasor positions within the yellow-orange spectral window centered at 590
nm. Bright CdSe/ZnS quantum dot, developed by NN-Labs, were employed as the
workhorse fluorescent species for modifications and targeting. Dynamic light scat-
tering and electron microscopy revealed 40 nm probes encapsulating quantum dots.
Probe surfaces were further treated with carboxylic acid and phosphonate functional
groups, as a basis for further modifications and promotion of aqueous dissolution.
Carbodiimide crosslinking reactions between carboxylic acid domains and primary
amines were used to conjugate thousands of PEG chains per probe. These PEG
molecules comprised of either long 35 or 36 block chains, or a combination of back-
filled 12 block short chains and long chains. While most chains terminated in an
nonreactive methoxy group, some had been retrofitted with azide moieties in order
to couple DBCO-MeTz linkers via a highly specific bioorthogonal click chemistry re-
action. Finalized MeTz-probes could then undergo a second rapid click chemistry
reaction by coupling to a premodified TCO-antibody.
TCO-MeTz reactions could either occur in-vitro via two-step targeting or through
the formation of immunoconjugates prior to direct targeting. Two-step targeting
initially showed non-backfilled probes were able to target biomarkers more effectively
than backfilled counterparts, however, large aggregates and non-specific binding of
probes was observed. Immunoconjugates were subsequently created and underwent
size exclusion chromatography. However, in the presence of protein, aggregation still
occurred. Future work will focus on removal of residual surfactant via incineration to
prevent protein adsorption. An alternative approach is to load anionic moieties onto
probe termini prior to addition of protein.
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With this work, we hope to test other probes encapsulating a specific mixture of
fluorescent species within our lifetime library in the yellow-orange spectral window.
We will then begin multiplexing select immunoconjugates to specific biomarkers of
interest, and finally, expand to other windows. Ultimately, we hope to use our life-
time library of probes to help rapidly identify a wide array of key biomarkers in
clinical settings in order to help rapidly develop successful personalized treatments
via biomarker-targeted therapies.
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Appendix A
Procedures
A.1 Reverse Microemulsion Synthesis
1) Add 10 mL of cyclohexane to a vial.
2) Add 1.3 mL of IGEPAL CO-520 to vial using syringe.
3) Add a magnetic stir bar then sonicate until clear.
4) Add quantum dots (QDs) while on stir plate (skip to step 6 if not using QDs)*.
5) Sonicate for 5 minutes.
6) Add dye-silane while on stir plate (skip to step 8 if not using dye-silane)*.
7) Sonicate for 5 minutes.
8) Add 150 μL of ammonia while on stir plate.
9) Sonicate for 1 minute.
10) Add 80 μL of TEOS while on stir plate.
11) Leave on stir plate for 24 hours.
12) Add 2 μL of CEST while on stir plate.
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13) Add 1 μL of TPMP while on stir plate.
14) Leave on stir plate for 24 hours.
15) Place 1 mL of sample solution in microcentrifuge tube.
16) Add 0.5 mL of ethanol to tube.
17) Centrifuge at 11,500 rcf for 15 minutes. Remove supernatant.
18) Add 1 mL of ethanol and sonicate until dissolved.
19) Repeat steps 17 - 18 three times, add 1 mL of ultrapure water on last wash.
20) Sonicate until dissolved and store sample at room temperature.
* The amounts of quantum dots or dye-silane can be variable. Unless otherwise
specified, we used 200 μL of CZ quantum dots (5 mg/mL in toluene) from NN-Labs.
A.2 Carbodiimide Crosslinker PEGylation
1) Perform calculations to determine reaction volumes.
2) Prepare ultrapure water, EDC, NHS, and PEG stock solutions. Vortex.
3) In microcentrifuge tube combine SNPs, Water, EDC, and NHS. Vortex.
4) Add PEGs to reaction mixture. Vortex and sonicate.
5) Incubate on nutator at room temperature for 3 hours. Sonicate every 20 minutes.
6) Transfer to Amicon Centrifugal Filter (100 kD) and add water to top off.
7) Centrifuge at 2000 rcf for 10 minutes. Remove follow through and add water.
8) Repeat three times. Add desired volume of water after last wash.
9) Sonicate until dissolved and store sample at room temperature.
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A.3 Methyltetrazine Linker Conjugation
1) Perform calculations to determine reaction volumes.
2) Prepare ultrapure water, DMF, and MeTz-DBCO stock solutions. Vortex.
3) In microcentrifuge tube combine SNPs, Water, and DMF. Vortex.
4) Add MeTz-DBCO to reaction mixture. Vortex and sonicate.
5) Incubate on nutator at room temperature for 24 hours.
6) Transfer to Amicon Centrifugal Filter (100 kD) and add water to top off.
7) Centrifuge at 2000 rcf for 10 minutes. Remove follow through and add water.
8) Repeat three times. Add desired volume of water after last wash.
9) Sonicate until dissolved and store sample at room temperature.
A.4 Trans-Cyclooctene Antibody Modification
1) Perform calculations to determine reaction volumes.
2) In microcentrifuge tube combine PBS, sodium bicarbonate, and antibody. Vortex.
3) Add DMF and NHS-TCO to solution. Vortex.
4) Incubate on nutator at room temperature for 3 hours.
5) To exchange buffer in Ziba Column, add 1 mL PBS slowly over column bed.
6) Centrifuge at 1000 rcf for 3 minutes. Remove follow through and add water.
7) Add 1 mL of water after last wash and obtain concentration with NanoDrop.
8) Store sample at 4 C.
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A.5 Biomarker Targeting
1) Perform calculations to determine reaction volumes.
2) After cells are sufficiently confluent, carefully aspirate media from well.
3) Add with 500 μL of PBS+ and carefully aspirate. Repeat twice.
4) Add TCO-antibodies or TCO-ICs in 150 μL PBS+. Incubate for 30 minutes.
5) Add with 500 μL of PBS+ and carefully aspirate. Repeat twice.
6) Add MeTz-probes in 150 μL PBS+. Incubate for 1 hour (skip if only using ICs).
7) Add with 500 μL of PBS+ and carefully aspirate. Repeat twice.
8) Add 150 μL PBS+. Analyze with phasor approach to FLIM.
A.6 Immunoconjugation
1) Perform calculations to determine reaction volumes.
2) In microcentrifuge tube combine PBS+, and modified antibody. Vortex.
3) Add Tz-probes to reaction solution. Vortex.
4) Incubate on nutator at room temperature for 1 hour.
5) Purify immunoconjugates using HPLC, S-400 or S-500 column.
6) Concentrate product in Amicon Centrifugal Filter (100 kD).
7) Store sample at 4 C.
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Appendix B
Calculations
B.1 Probe Count
volQD = 200 µL volQD stock = 5000 µL MQD stock = 5.0 µM
molQD stock =
5.0 µmol
L
∗ 0.005 L = 25 nmol
molQDs in rxn = molQD stock ∗ 200 µL5000 µL = 1.0 nmol
numberQDs in rxn = molQDs in rxn ∗ 6.022∗1023 molecules1 mol ≈ 6.0 ∗ 1014 QDs
At 1 QD per Probe ≈ 6.0 ∗ 1014 Probes per reaction
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B.2 Surface Moieties
Silicon Distancecryst = 0.323 nm ρamorph = 2.196
g
mL
ρcryst = 2.648
g
mL
Silicon Distanceamorph = 0.323 nm ∗
(
2.196 g
mL
2.648 g
mL
)−1
= 0.388 nm
Silicon Distance2amorph = (0.388 nm)
2 = 0.152 nm2
Silicon Atoms per nm2 = 1
0.152
≈ 6.58
Surface Area = 4pi(40 nm
2
)2 = 5026 nm2
Bind sites per Probe = 5026 nm2 ∗ 6.58 sites
nm2
≈ 33070
CEST: 2 µL ∗ 1
103
mL
µL
∗ 1.170
1
g
mL
∗ 1
196.4
mol
g
∗ 0.25 wt% = 2.983 ∗ 10−6 mol
TPMP: 1 µL ∗ 1
103
mL
µL
∗ 1.252
1
g
mL
∗ 1
238.2
mol
g
∗ 0.50 wt% = 2.628 ∗ 10−6 mol
CEST per Probe ≈ 33070 sites ∗ ( 2.983
2.983+2.628
) ≈ 17580
Estimated PEG per nm2 ≈ 6.0 [9]
Max PEG per Probe ≈ 6.0
6.58
∗ 17580 ≈ 16040
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